Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study - The Lancet Oncology

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. - Abstract - Europe PMC

Frontiers Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies

Pharmaceutics, Free Full-Text

Frontiers Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial - The Lancet Oncology

Contemporary Treatment of Metastatic Non-Small Cell Lung Cancer - ppt download

View of Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies

PDF] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Cancers, Free Full-Text

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial, BMC Cancer